Pharmacokinetics, Pharmacodynamics, & Drug Metabolism Community

 View Only
Back to discussions
Expand all | Collapse all

Immunogenicity Risk Assessment Tools and their utility in the light of New Approach Methodologies or NAMs

  • 1.  Immunogenicity Risk Assessment Tools and their utility in the light of New Approach Methodologies or NAMs

    Community Leadership
    Posted 08-14-2025 09:48

    We have received great response to my original post for initiating discussions on utility of current in silico and in vitro tools that can be repurposed for addressing preclinical development related questions on safety and toxicity due to drug product exposure.  

    We will kick off a meeting soon

    Thanks to those who have expressed interest and also provided your email contacts to join this working group.



    ------------------------------
    Vibha Jawa
    Chief Scientific Officer
    Epivax
    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: Immunogenicity Risk Assessment Tools and their utility in the light of New Approach Methodologies or NAMs

    Posted 08-15-2025 10:47

    Hi, 

    My name is Krishna, and I am currently working as a Senior Scientist, Biopharmaceutics at Sanofi. I am interested in joining the working group and would greatly appreciate your assistance in becoming a member. 

    Thanks & Regards,

    Krishna



    ------------------------------
    Venkata Krishna Kowthavarapu
    Postdoctoral Associate
    University of Florida
    Orlando FL
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------

    Original Message